<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                               NIH Public Access <br />                                Author Manuscript <br />                                Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                            Published final edited form  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Mol Biochem Parasitol. 2011 January ; 175(1): 21&#226;&#8364;&#8220;29. doi:10.1016/j.molbiopara.2010.08.005. <br />  <br />  <br />  <br />                            Identification inhibitors putative malaria drug targets <br />                            novel antimalarial compounds <br />                            Gregory J. Crowthera, Alberto J. Napulia, James H. Gilliganb, Kerstin Gagaringb, Rachel <br />                            Borboab, Carolyn Francekb, Zhong Chenb, Eleanor F. Dagostinob, Justin B. Stockmyerb, Yu <br />                            Wangb, Philip P. Rodenbougha, Lisa J. Castanedaa, David J. Leiblya, Janhavi Bhandaria, <br />                            Michael H. Gelba, Achim Brinkerb, Ingo Engelsb, Jennifer Taylorb, Arnab K. Chatterjeeb, <br />                            Pascal Fantauzzic, Richard J. Glynneb, Wesley C. Van Voorhisa, Kelli L. Kuhenb <br />  <br />                            aUniversity Washington, Seattle, WA, USA b Genomics Institute Novartis Research <br />                            Foundation (GNF), San Diego, CA, USA c Medicines Malaria Venture, Geneva, Switzerland <br />  <br />                            Abstract <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                  efficacy marketed antimalarial drugs compromised evolution parasite <br />                                  resistance, underscoring urgent need new drugs new mechanisms action.                                  taken high-throughput approach identifying novel antimalarial <span id='am-1' about='obo:IMR_0000947' typeof='owl:Thing obo:IMR_0000001'><span id='am-2' property="rdfs:label" content="chemical" datatype="xsd:string"></span><span id='am-3' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:id" content="IMR:0000947" datatype="xsd:string"></span>chemical</span> inhibitors <br />                                  prioritized drug targets P. falciparum, excluding targets inhibited currently <br />                                  used drugs. screen commercially available libraries identified 5,655 low molecular weight <br />                                  compounds inhibit growth P. falciparum cultures EC50 values 1.25 &#206;&#188;M.                                  compounds tested 384- 1536 biochemical assays activity                                  Plasmodium enzymes: adenylosuccinate synthetase (AdSS), choline kinase (CK), deoxyuridine <br />                                  <span id='am-119' about='obo:IMR_0200358' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-120' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-121' property="oboInOwl:hasDbXref" content="KEGG:C00536" datatype="xsd:string"></span><span id='am-122' property="oboInOwl:id" content="IMR:0200358" datatype="xsd:string"></span><span id='am-123' property="rdfs:label" content="Triphosphate" datatype="xsd:string"></span>triphosphate</span> nucleotidohydrolase (dUTPase), glutamate dehydrogenase (GDH), guanylate kinase <br />                                  (GK), N-myristoyltransferase (NMT), orotidine 5&#226;&#8364;&#178;-monophosphate decarboxylase (OMPDC), <br />                                  farnesyl <span id='am-51' about='obo:IMR_0200280' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-52' property="oboInOwl:id" content="IMR:0200280" datatype="xsd:string"></span><span id='am-53' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-54' property="oboInOwl:hasDbXref" content="KEGG:C00013" datatype="xsd:string"></span><span id='am-55' property="rdfs:label" content="Pyrophosphate" datatype="xsd:string"></span>pyrophosphate</span> synthase (FPPS) S-adenosylhomocysteine hydrolase (SAHH).                                  enzymes selected using TDRtargets.org, believed excellent potential drug <br />                                  targets based criteria likely essentiality, druggability, amenability high- <br />                                  throughput biochemical screening. targets inhibited                                  antimalarial scaffolds potential use drug development, target validation <br />                                  studies exploration P. falciparum biochemistry biology. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            Keywords <br />                                  target-based drug development; enzyme activity assays; antimalarial compounds <br />  <br />  <br />                            1. Introduction <br />                                              Approximately 3 billion people, half world&#226;&#8364;&#8482;s population, live risk regions                                              malaria infection. leads 250 million malaria cases year nearly  <br />  <br />                            &#194;&#169; 2010 Elsevier B.V. rights reserved. <br />                            Corresponding author: K.L.K., Genomics Institute Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San <br />                            Diego CA 92121, USA; phone: 858-812-1819; fax: 858-812-1819; kkuhen@gnf.org. <br />                            Publisher&apos;s Disclaimer: PDF file unedited manuscript accepted publication. service                            customers providing early version manuscript. manuscript undergo copyediting, typesetting, review                            resulting proof published final citable form. note production process errors                            discovered affect content, legal disclaimers apply journal pertain. <br />                             Crowther et al.                                                                                             Page 2 <br />  <br />  <br />                                              million deaths (World Malaria Report,  2009, <br />                                              http://www int/malaria/world_malaria_report_2009 index.html). etiologic agent <br />                                              Plasmodium falciparum organism responsible majority deaths NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              malaria, 90% occur Africa 85% children age 5. <br />                                              presence widespread drug resistance hampering effectiveness                                              available drug arsenal [1&#226;&#8364;&#8220;6] notable exception artemisinin-based derivatives. <br />                                              Artemisinin-based combination therapies (ACT) recommended line treatments <br />                                              falciparum malaria countries endemic disease [7]. ACT remains <br />                                              effective, recent concerns efficacy artemisinin-based derivatives                                              declined Thai-Cambodian border [8&#226;&#8364;&#8220;10]. Potential clinical resistance closely <br />                                              monitored areas Southeast Asia artemisinin used monotherapy                                              decades antimalarial drug resistance previously developed. potential <br />                                              development artemisinin resistance parasite loss ACT crisis,                                              ACTs recommended worldwide new agents currently phase 3 clinical <br />                                              trials based ACT. battle fight malaria, introduction new drugs novel <br />                                              mechanisms action essential. <br />  <br />                                              Data essentiality putative drug targets Plasmodium growth limited                                              individual genes tested gene disruption studies [11&#226;&#8364;&#8220;19].  <br />                                              chemical inhibition target genetic essentiality does translate                                              pharmacological efficacy pathogen [20], genetic data essentiality <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              available comprehensive genome-wide dataset Plasmodium. Inhibition P. <br />                                              falciparum replication chemical inhibition potential drug targets  instead, <br />                                              provide chemical validation targets. end, undertook effort provide <br />                                              chemical tools explore biology prioritized Plasmodium targets, provide                                              starting point chemical validation targets. developed biochemical assays                                              test enzymatic activity prioritized targets. set compounds                                              pre-annotated having inhibitory activity P. falcpiarum proliferation erythrocytes <br />                                              tested inhibitory activity biochemical assays. reasoned                                              screening compounds known cell-based activity   <br />                                              address issues plagued biochemical approaches. include <br />                                              cellular permeability, efflux metabolism small-molecule inhibitors. <br />  <br />                                              screened GNF&#226;&#8364;&#8482;s non-proprietary compound collection identified subset                                              5,655 compounds potent inhibitory activity P. falciparum growth vitro                                              described [21]. compounds non-proprietary available <br />                                              commercially, facilitating broad exploration mechanism action academic <br />                                              community. structures compounds available                                              http://www.ebi.ac.uk/chembldb/ http://www.TDRtargets.org/. included NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              dataset dose-response data activity strains P. falciparum, 3D7 W2,                                              EC50 values, cytotoxicity information human hepatocellular carcinoma cell <br />                                              line Huh7, measure promiscuity compounds historical high- <br />                                              throughput screens conducted GNF. available, compounds tested  <br />                                              ordered powders supplier. collection screened high-throughput <br />                                              biochemical assays Plasmodium enzymes considered promising drug <br />                                              targets based data compiled TDRtargets.org [22] literature data.                                              results target-based biochemical screens discussed  Notably                                              identified chemical inhibitors 6 9 targets tested sub-library                                              thousand compounds, preselected cellular activity. <br />  <br />  <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                              Page 3 <br />  <br />  <br />                               2. Materials methods <br />                               2.1. Identification antimalarial compounds <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              high-throughput screen GNF&#226;&#8364;&#8482;s non-proprietary compound collection performed <br />                                              using erythrocyte-based P. falciparum strain 3d7 infection assay essentially described <br />                                              [21]. Compounds screened 1.25 &#206;&#188;M; hits inhibiting growth                                              &#226;&#8240;&#165;50% reconfirmed dose-response format determine EC50 values, cellular <br />                                              cytotoxicity (quantified CC50) assessed Huh7 hepatocellular carcinoma cell <br />                                              line. Compounds selectivity index &lt;5 (CC50/EC50) excluded                                              consideration, compounds quench fluorescence. Reconfirmed hit <br />                                              compounds (5,655 total) ordered powders 3,086 compounds                                              available purchase suppliers. <br />  <br />                               2.2. Target selection <br />                                              selecting enzymes screen (Table 1), employed TDRtargets.org [22]                                              sources identify Plasmodium enzymes candidates compound screening using                                              following criteria:  enzyme likely required survival parasite; ii)                                              enzyme small-molecule binding pocket exploited drug-like <br />                                              molecule inhibit enzymatic activity; iii) exploitable differences                                              parasite human enzymes pathways belong drug NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              developed minimal adverse effects host; iv) enzyme amenable                                              recombinant expression  precedent selected targets [23&#226;&#8364;&#8220;30];                                              v) enzymatic activity measured high-throughput format. criteria                                              focused especially  iv, v druggability (ii) selectivity (iii) currently <br />                                              difficult predict.  example  difluoromethylornithine inhibits                                              human T. brucei ornithine decarboxylases, selectively kills T. brucei cells, <br />                                              apparently rapid turnover human enzyme [31].)                                              enzymes chosen criteria adenylosuccinate synthetase (AdSS), choline kinase <br />                                              (CK), deoxyuridine triphosphate nucleotidohydrolase (dUTPase), farnesyl pyrophosphate <br />                                              synthase (FPPS), glutamate dehydrogenase (GDH), guanylate kinase (GK), N- <br />                                              myristoyltransferase (NMT), orotidine 5&#226;&#8364;&#178;-monophosphate decarboxylase (OMPDC), S- <br />                                              adenosylhomocysteine hydrolase (SAHH). <br />  <br />                               2.3 Expression purification recombinant Plasmodium proteins <br />                                              Recombinant histidine-tagged enzymes Plasmodium falciparum P. vivax                                              expressed Escherichia coli purified immobilized metal affinity chromatography, <br />                                              essentially described previously [32]. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               2.4 Biochemical assay details <br />                                              Specific activities enzymes studied reported previously [33],                                              comparisons literature values possible. <br />  <br />                                              Enzyme activity assays miniaturized optimized 1536 plates test <br />                                              compounds screened dose-response format 12 points &#194;&#189;-log serial dilutions <br />                                              (0.0005 &#226;&#8364;&#8220; 100 &#206;&#188;M), exception SAHH, screened single-point format <br />                                              384 plates. Incubations room temperature unless noted.                                              reactions included final [DMSO] 1%. initial collection antimalarial compounds <br />                                              available set DMSO solutions pre-existing GNF compound library <br />                                              (available formats: 5,655 compounds, 1536 dose-response format; 5,543 compounds, <br />                                              384 single point format), 6 targets screened using collections (Table 3). <br />                                              original stocks antimalarial compounds depleted, remaining <br />                                              targets (FPPS, dUTPase, NMT) screened using DMSO solutions reconstituted <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                             Page 4 <br />  <br />  <br />                                              3,086 compounds available repurchasing time screens. Hits                                              reconfirmed using ordered purified powders available vendor tested <br />                                              dose-response format. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              Chemical reactions detection strategies enzyme shown Table 2; <br />                                              additional details noted  general, assay concentrations substrates                                              approximately 3 times respective Km&#226;&#8364;&#8482;s. Compounds, general, added enzyme <br />                                              buffer reagents 10 minutes prior initiation reaction addition substrate.                                              compounds hit multiple target-based assays triaged lack specificity <br />                                               e., likely false positives) included final hit list (Supplementary Table S1). <br />  <br />                                              AdSS assayed buffer 50 mM Tris, pH 7.0, 5 mM DTT, 0.1% BSA, 0.001% <br />                                              Tween-20, 2.5 mM MgCl2. Final concentrations 500 ng/mL AdSS (10 nM), 30 <br />                                              &#206;&#188;M <span id='am-20' about='obo:IMR_0001354' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-21' property="oboInOwl:hasExactSynonym" content="guanosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-22' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-23' property="oboInOwl:id" content="IMR:0001354" datatype="xsd:string"></span><span id='am-24' property="oboInOwl:hasAlternativeId" content="IMR:0200086" datatype="xsd:string"></span><span id='am-25' property="rdfs:label" content="guanosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-26' property="rdfs:label" content="GTP" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:hasDbXref" content="KEGG:C00044" datatype="xsd:string"></span>GTP</span>, 60 &#206;&#188;M <span id='am-239' about='obo:IMR_0200221' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-240' property="oboInOwl:hasDbXref" content="KEGG:C00130" datatype="xsd:string"></span><span id='am-241' property="oboInOwl:id" content="IMR:0200221" datatype="xsd:string"></span><span id='am-242' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-243' property="rdfs:label" content="IMP" datatype="xsd:string"></span>IMP</span>, 1 mM aspartate. Incubation time 40 minutes,                                              <span id='am-33' about='obo:IMR_0001357' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-34' property="rdfs:label" content="GDP" datatype="xsd:string"></span><span id='am-35' property="oboInOwl:hasAlternativeId" content="IMR:0200191" datatype="xsd:string"></span><span id='am-36' property="oboInOwl:id" content="IMR:0001357" datatype="xsd:string"></span><span id='am-37' property="oboInOwl:hasDbXref" content="KEGG:C00035" datatype="xsd:string"></span><span id='am-38' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>GDP</span> produced AdSS detected Transcreener GDP detection mix (Cisbio), <br />                                              used according manufacturer&#226;&#8364;&#8482;s instructions. Homogeneous time-resolved fluorescence <br />                                              (HTRF) GDP produced monitored excitation 337 nm dual emission                                              620 665 nm. <br />  <br />                                              CK assayed buffer 100 mM HEPES, pH 7.5, 150 mM NaCl 1 mM <br />                                              MgCl2. Final concentrations 312.5 ng/mL CK (5 nM), 10 &#206;&#188;M <span id='am-93' about='obo:IMR_0001351' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-94' property="rdfs:label" content="adenosine triphosphate" datatype="xsd:string"></span><span id='am-95' property="oboInOwl:hasDbXref" content="KEGG:C00002" datatype="xsd:string"></span><span id='am-96' property="oboInOwl:hasExactSynonym" content="adenosine triphosphate" datatype="xsd:string"></span><span id='am-97' property="oboInOwl:id" content="IMR:0001351" datatype="xsd:string"></span><span id='am-98' property="rdfs:label" content="ATP" datatype="xsd:string"></span><span id='am-99' property="oboInOwl:hasExactSynonym" content="adenosine 5&apos;-triphosphate" datatype="xsd:string"></span><span id='am-100' property="oboInOwl:hasAlternativeId" content="IMR:0200394" datatype="xsd:string"></span><span id='am-101' property="oboInOwl:hasAlternativeId" content="IMR:0100127" datatype="xsd:string"></span><span id='am-102' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-103' property="rdfs:label" content="adenosine 5&apos;-triphosphate" datatype="xsd:string"></span>ATP</span>, 280 &#206;&#188;M <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              choline. Incubation time 30 minutes, <span id='am-39' about='obo:IMR_0001360' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-40' property="oboInOwl:hasAlternativeId" content="IMR:0200375" datatype="xsd:string"></span><span id='am-41' property="oboInOwl:id" content="IMR:0001360" datatype="xsd:string"></span><span id='am-42' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-43' property="oboInOwl:hasDbXref" content="KEGG:C00008" datatype="xsd:string"></span><span id='am-44' property="rdfs:label" content="ADP" datatype="xsd:string"></span>ADP</span> produced CK                                              detected Transcreener ADP detection mix (Cisbio), AdSS. <br />  <br />                                              dUTPase assayed buffer 25 mM MOPS, pH 8.0, 10 mM KCl, 1.25 mM <br />                                              MgCl2, 0.1 mg/mL BSA, 0.005% Triton X 20% glycerol. Final concentrations 2 <br />                                              ng/mL dUTPase (97 pM) 14 &#206;&#188;M <span id='am-109' about='obo:IMR_0200056' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-110' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-111' property="oboInOwl:hasDbXref" content="KEGG:C00460" datatype="xsd:string"></span><span id='am-112' property="oboInOwl:id" content="IMR:0200056" datatype="xsd:string"></span><span id='am-113' property="rdfs:label" content="dUTP" datatype="xsd:string"></span>dUTP</span>. Incubation time 30 minutes. Production                                              PPi monitored PPiLight kit (Lonza) conversion ATP measurement                                              luminescent signal corresponding [ATP]. PPi detection mix diluted 1:4                                              reaction buffer prior use. <br />  <br />                                              FPPS assayed buffer 50 mM HEPES, pH 7.5, 0.625 mM MgCl2, 1 mM <br />                                              NaCl, 0.25 mM TCEP, 5% BSA, 10% glycerol, 0.01% Triton X-100. Final <br />                                              concentrations 1.3 &#206;&#188;g/mL FPPS (45 nM), 25 &#206;&#188;M <span id='am-249' about='obo:IMR_0200399' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-250' property="oboInOwl:hasDbXref" content="KEGG:C00341" datatype="xsd:string"></span><span id='am-251' property="oboInOwl:id" content="IMR:0200399" datatype="xsd:string"></span><span id='am-252' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-253' property="rdfs:label" content="Geranyl diphosphate" datatype="xsd:string"></span>geranyl diphosphate</span>, 25 &#206;&#188;M <br />                                              <span id='am-56' about='obo:IMR_0200287' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-57' property="rdfs:label" content="Isopentenyl diphosphate" datatype="xsd:string"></span><span id='am-58' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-59' property="oboInOwl:hasDbXref" content="KEGG:C00129" datatype="xsd:string"></span><span id='am-60' property="oboInOwl:id" content="IMR:0200287" datatype="xsd:string"></span>isopentenyl diphosphate</span>. Incubation time 30 minutes. Production PPi monitored <br />                                              PPiLight kit (Lonza), dUTPase. <br />  <br />                                              GDH assayed buffer 100 mM Tris, pH 8.0, 1 mM DTT, 0.1 mg/mL BSA, <br />                                              0.005% Triton X-100. Final concentrations 0.5 &#206;&#188;g/mL GDH (10 nM), 400 &#206;&#188;M <br />                                              NADP+, 10 mM glutamate. Incubation time 45 minutes. fluorescence NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              <span id='am-83' about='obo:IMR_0200463' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-84' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-85' property="oboInOwl:hasDbXref" content="KEGG:C00005" datatype="xsd:string"></span><span id='am-86' property="rdfs:label" content="NADPH" datatype="xsd:string"></span><span id='am-87' property="oboInOwl:id" content="IMR:0200463" datatype="xsd:string"></span>NADPH</span> produced monitored excitation 355 nm emission 486 nm. <br />  <br />                                              GK assayed buffer 50 mM Tris, pH 7.5, 50 mM KCl, 2 mM MgCl2 0.1 <br />                                              mg/mL BSA. Final concentrations 1.5 ng/mL GK (130 pM), 7 &#206;&#188;M <span id='am-224' about='obo:IMR_0200292' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-225' property="rdfs:label" content="GMP" datatype="xsd:string"></span><span id='am-226' property="oboInOwl:hasDbXref" content="KEGG:C00144" datatype="xsd:string"></span><span id='am-227' property="oboInOwl:id" content="IMR:0200292" datatype="xsd:string"></span><span id='am-228' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>GMP</span>, 10 &#206;&#188;M <br />                                              ATP. Incubation time 20 minutes, ADP GDP produced GK                                              detected Transcreener ADP detection mix (Cisbio), AdSS. <br />  <br />                                              NMT assayed buffer 50 mM Tris, pH 7.5, 6.25 mM NaCl, 0.625 mM <br />                                              MgCl2, 10% BSA, 0.005% Triton X-100. Final concentrations 1.5 &#206;&#188;g/mL NMT <br />                                              (30 nM), 15 uM myristoyl-<span id='am-114' about='obo:IMR_0200354' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-115' property="oboInOwl:hasDbXref" content="KEGG:C00010" datatype="xsd:string"></span><span id='am-116' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-117' property="rdfs:label" content="CoA" datatype="xsd:string"></span><span id='am-118' property="oboInOwl:id" content="IMR:0200354" datatype="xsd:string"></span>CoA</span>, 90 uM GSSYSRKNK, synthetic <span id='am-5' about='obo:IMR_0001700' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-6' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-7' property="obo:IAO_0000115" content="The polypeptide that is not a gene product." datatype="xsd:string"></span><span id='am-8' property="oboInOwl:id" content="IMR:0001700" datatype="xsd:string"></span><span id='am-9' property="rdfs:label" content="peptide" datatype="xsd:string"></span>peptide</span> obtained <br />                                              Peptides International GenScript order parameters 85% purity                                              N- C-terminal modifications. peptide based N-terminal sequence                                              adenylate kinase 2, substrate N-myristoyltransferase P. falciparum vivo [34]. <br />                                              Incubation time 45 minutes 30 &#194;&#176;C, ThioGlo [35] added final <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                             Page 5 <br />  <br />  <br />                                              concentration 15 &#206;&#188;M detect free &#226;&#8364;&#8220;SH groups CoA produced NMT. ThioGlo <br />                                              fluorescence monitored excitation 360 nm emission 540 nm. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              OMPDC assayed buffer 100 mM Tris, pH 8.0, 50 mM NaCl, 1 mM MgCl2, <br />                                              1 mM DTT, 0.3 mg/mL BSA. Final concentrations 3 ng/mL OMPDC (77 pM), 2 <br />                                              &#206;&#188;M OMP, 1 &#206;&#188;M ATP, 1 &#206;&#188;g/mL human <span id='am-244' about='obo:IMR_0200494' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-245' property="oboInOwl:hasDbXref" content="KEGG:C00055" datatype="xsd:string"></span><span id='am-246' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-247' property="oboInOwl:id" content="IMR:0200494" datatype="xsd:string"></span><span id='am-248' property="rdfs:label" content="CMP" datatype="xsd:string"></span>CMP</span> kinase [36], used convert <br />                                              <span id='am-213' about='obo:IMR_0200409' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-214' property="oboInOwl:id" content="IMR:0200409" datatype="xsd:string"></span><span id='am-215' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-216' property="rdfs:label" content="UMP" datatype="xsd:string"></span><span id='am-217' property="oboInOwl:hasDbXref" content="KEGG:C00105" datatype="xsd:string"></span>UMP</span> (produced OMPDC) + ATP <span id='am-254' about='obo:IMR_0200206' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-255' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-256' property="oboInOwl:id" content="IMR:0200206" datatype="xsd:string"></span><span id='am-257' property="oboInOwl:hasDbXref" content="KEGG:C00015" datatype="xsd:string"></span><span id='am-258' property="rdfs:label" content="UDP" datatype="xsd:string"></span>UDP</span> + ADP. Incubation time 180 minutes, <br />                                              ADP detected Transcreener ADP detection mix (Cisbio),                                              AdSS. <br />  <br />                                              SAHH assayed buffer 50 mM potassium phosphate, pH 8.0. Final concentrations <br />                                              5 &#206;&#188;g/mL SAHH (100 nM), 4 &#206;&#188;M S-adenosylhomocysteine, 2.5 &#206;&#188;g/mL <span id='am-142' about='obo:IMR_0100126' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001697 obo:IMR_0000001 obo:IMR_0001698'><span id='am-143' property="oboInOwl:hasAlternativeId" content="IMR:0200246" datatype="xsd:string"></span><span id='am-144' property="oboInOwl:hasExactSynonym" content="9-B-D-ribofuranosyl-9H-purin-6-amine" datatype="xsd:string"></span><span id='am-145' property="oboInOwl:id" content="IMR:0100126" datatype="xsd:string"></span><span id='am-146' property="oboInOwl:hasDbXref" content="KEGG:C00212" datatype="xsd:string"></span><span id='am-147' property="rdfs:label" content="Ribofuranosyladenine" datatype="xsd:string"></span><span id='am-148' property="oboInOwl:hasExactSynonym" content="Ribofuranosyladenine" datatype="xsd:string"></span><span id='am-149' property="rdfs:label" content="9-B-D-ribofuranosyl-9H-purin-6-amine" datatype="xsd:string"></span><span id='am-150' property="oboInOwl:hasExactSynonym" content="Adenine riboside" datatype="xsd:string"></span><span id='am-151' property="obo:IAO_0000115" content="A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter." datatype="xsd:string"></span><span id='am-152' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-153' property="oboInOwl:hasExactSynonym" content="Adenosine" datatype="xsd:string"></span><span id='am-154' property="rdfs:label" content="adenosine" datatype="xsd:string"></span><span id='am-155' property="rdfs:label" content="Adenine riboside" datatype="xsd:string"></span><span id='am-156' property="rdfs:label" content="Adenosine" datatype="xsd:string"></span>adenosine</span> <br />                                              deaminase P. falciparum (added consume <span id='am-157' about='obo:IMR_0100126' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001697 obo:IMR_0000001 obo:IMR_0001698'><span id='am-158' property="oboInOwl:hasAlternativeId" content="IMR:0200246" datatype="xsd:string"></span><span id='am-159' property="rdfs:label" content="adenosine" datatype="xsd:string"></span><span id='am-160' property="oboInOwl:hasDbXref" content="KEGG:C00212" datatype="xsd:string"></span><span id='am-161' property="oboInOwl:id" content="IMR:0100126" datatype="xsd:string"></span><span id='am-162' property="rdfs:label" content="Adenosine" datatype="xsd:string"></span><span id='am-163' property="obo:IAO_0000115" content="A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter." datatype="xsd:string"></span><span id='am-164' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-165' property="rdfs:label" content="Adenine riboside" datatype="xsd:string"></span><span id='am-166' property="oboInOwl:hasExactSynonym" content="Ribofuranosyladenine" datatype="xsd:string"></span><span id='am-167' property="oboInOwl:hasExactSynonym" content="9-B-D-ribofuranosyl-9H-purin-6-amine" datatype="xsd:string"></span><span id='am-168' property="oboInOwl:hasExactSynonym" content="Adenosine" datatype="xsd:string"></span><span id='am-169' property="rdfs:label" content="9-B-D-ribofuranosyl-9H-purin-6-amine" datatype="xsd:string"></span><span id='am-170' property="oboInOwl:hasExactSynonym" content="Adenine riboside" datatype="xsd:string"></span><span id='am-171' property="rdfs:label" content="Ribofuranosyladenine" datatype="xsd:string"></span>adenosine</span> produced SAHH, <br />                                              promoting continued progress forward reaction). Incubation time 90 minutes, <br />                                              ThioGlo [35] added final concentration 25 &#206;&#188;M detect free &#226;&#8364;&#8220;SH <br />                                              groups homocysteine produced SAHH. ThioGlo fluorescence monitored                                              excitation 360 nm emission 540 nm. SAHH screen unique                                              compounds initially tested single concentration 8.3 &#206;&#188;M;  initial hits <br />                                              defined compounds inhibiting SAHH &#226;&#8240;&#165;25% concentration. <br />  <br />                               3. Results <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               3.1. Identification antimalarial compounds <br />                                              identified set 5,655 compounds inhibit growth P. falciparum erythrocytes <br />                                              described [21]. ~7,500 primary screen hits tested 8-point dose-response curves <br />                                              reconfirmation antimalarial activity EC50 value determination drug- <br />                                              resistant strains: sulfadoxine-resistant 3D7 strain multi-drug resistant W2 strain <br />                                              (resistant chloroquine, quinine, pyrimethamine, sulfadoxine, cycloguanil). Known <br />                                              inhibitors compound collection (e.g., artemisinin, mefloquine, dihydrofolate reductase <br />                                              inhibitors, quinine) identified, providing internal validation assay sensitivity. <br />                                              Counterscreens included fluorescence quencher assessment cytotoxicity Huh7 <br />                                              human hepatocellular carcinoma cell line. Compounds EC50 &lt; 1.25 &#206;&#188;M P. <br />                                              falciparum 3d7 W2 strains selectivity index (SI) Huh7 cell line                                              5-fold did exhibit fluorescence quenching retained study. <br />  <br />                               3.2. Choline kinase <br />                                              CK catalyzes step synthesis phosphatidylcholine, essential                                              intraerythrocytic growth Plasmodium parasite [26, 37, 38]. Km CK choline <br />                                              determined ~200 &#206;&#188;M, consistent value 140 &#206;&#188;M reported [26]. NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              chemical inhibitor hexadecyltrimethylammonium bromide (HDTAB) used                                              positive control CK inhibition [37];  physicochemical properties HDTAB <br />                                              interfered homogeneous time resolved fluorescence (HTRF) signal detection. <br />  <br />                                              listed Table 2, CK screen resulted 69 hits 1.2% hit rate. IC50 values ranged <br />                                              0.06 &#206;&#188;M 11 &#206;&#188;M P. falciparum EC50 values ranged 0.013 &#206;&#188;M 1.25 <br />                                              &#206;&#188;M. 23 powders available reconfirmation powders, reconfirmed                                              triplicate IC50 values ranging 2.9 &#206;&#188;M 19.0 &#206;&#188;M. Corresponding P. falciparum <br />                                              EC50 values 10-fold potent. hits identified                                               Supplementary Table S1), compound CK-1  3-chlorobenzothiophene amide; shown                                              Figure 1A) chemically tractable structure suitable starting point                                              chemical optimization. CK-2 CK-3 (Fig. 1A) analogs scaffold.                                              activities enzyme weaker (20-fold) cell-based activities, rank orders <br />  <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                          Page 6 <br />  <br />  <br />                                              potency compounds cell-based target-based <br />                                              assays. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               3.3. S-Adenosylhomocysteine hydrolase <br />                                              SAHH, component methylation cycle methyl groups donated lipids, <br />                                              nucleic acids, proteins, molecules, certainly essential highly <br />                                              druggable (Table 1). similarity parasite human active sites concern,                                              residue adenosine binding site &#226;&#8364;&#8220; Cys59 PfSAHH, Thr60 HsSAHH &#226;&#8364;&#8220; <br />                                              differing [39]. Km SAHH S-adenosylhomocysteine                                              determined ~2 &#206;&#188;M, close literature value 1.2 &#206;&#188;M [24]. SAHH screen <br />                                              resulted 38 hits hit rate 0.68% (Table 2). 20 powders 38 hits                                              available,  seven compounds reconfirmed dose-response format                                              triaged based overlap target screens (AdSS, , suggesting                                              promiscuous inhibitors. IC50 values ranged 0.1 &#206;&#188;M 9.1 &#206;&#188;M                                              corresponding P. falciparum EC50 values ranged 0.9 &#206;&#188;M 7.6 &#206;&#188;M.                                              reconfirmed specific hits identified (Supplementary Table S1), SAHH-1 (Fig. 1B)                                              interesting 8-hydroxyquinoline-based hit serve potential starting point                                              medicinal chemistry. hits tool compounds,                                              chemically attractive drug discovery, include SAHH-2, quinazosin, known <br />                                              vasodilator alpha-1 adrenergic receptor target [40] SAHH-3, known                                              phanquinone, antimicrobial agent [41]. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               3.4. Enzymes involved <span id='am-124' about='obo:IMR_0001349' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001698'><span id='am-125' property="obo:IAO_0000115" content="A nucleotide consists of a nitrogen-containing base, a five-carbon sugar, and one or more phosphate groups. Nucleotides can carry chemical energy (e.g. ATP), form coenzymes (e.g. CoA), be used as specific signaling molecules (e.g. cAMP) in the cell. Nucleotides are the subunits of the nucleic acids. " datatype="xsd:string"></span><span id='am-126' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-127' property="oboInOwl:id" content="IMR:0001349" datatype="xsd:string"></span><span id='am-128' property="rdfs:label" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-129' property="rdfs:label" content="nucleotide" datatype="xsd:string"></span><span id='am-130' property="oboInOwl:hasExactSynonym" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-131' property="oboInOwl:hasDbXref" content="CHEBI:25608" datatype="xsd:string"></span>nucleotide</span> metabolism (AdSS, dUTPase, GK, OMPDC) <br />                                              AdSS, purine salvage pathway, obtained Km values 14 &#206;&#188;M IMP, <br />                                              105 &#206;&#188;M GTP, 0.05 mM aspartate, somewhat different previously <br />                                              reported values 22.8 &#206;&#188;M, 4.8 &#206;&#188;M, 1.4 mM, respectively [29]. AdSS screen <br />                                              resulted 9 hits 0.2% hit rate (Table 2). Hadacidin used positive control <br />                                              inhibitor [42], IC50 value 62 &#206;&#188;M. hits, available powders                                              reconfirmed. compounds triaged inhibited SAHH activity, <br />                                              leaving 3 candidate AdSS inhibitors (Supplementary Table S1).                                               compounds unlikely starting points medicinal chemistry chemically labile <br />                                              functionalities sulfonylureas (AdSS-1), imines derived aldehydes (AdSS-2) <br />                                              quaternary aromatic amines (AdSS-3). AdSS-1 (Fig. 1C), N-sulfonylurea,                                              useful tool compound;  publicly available information cites cytostatic <br />                                              mechanism action human cells  PubChem: 120394059 120394064). AdSS-2 (Fig. <br />                                              1C), benzyaldehydederived imine, relatively specific malaria inhibition;                                              compound useful tool compound AdSS. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              GK selected target based involvement nucleic acid synthesis. GK converts <br />                                              (d)GMP (d)GDP, turn used make (d)GTP, essential nucleic <br />                                              acid synthesis. likely essentiality GK   doubt, Plasmodium <br />                                              thymidylate kinase (2.7.4.9) convert <span id='am-10' about='obo:IMR_0200505' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-11' property="rdfs:label" content="dGMP" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:id" content="IMR:0200505" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:hasDbXref" content="KEGG:C00362" datatype="xsd:string"></span>dGMP</span> <span id='am-234' about='obo:IMR_0200365' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-235' property="rdfs:label" content="dGDP" datatype="xsd:string"></span><span id='am-236' property="oboInOwl:id" content="IMR:0200365" datatype="xsd:string"></span><span id='am-237' property="oboInOwl:hasDbXref" content="KEGG:C00361" datatype="xsd:string"></span><span id='am-238' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>dGDP</span> [43, 44]. additional <br />                                              enzyme, ribonucleoside-diphosphate reductase (1.17.4.1), convert dGDP GDP.  <br />                                              GK blocked, (d)GDP dGMP.                                               expression GK liver stage Plasmodium life cycle [45] suggests possible <br />                                              importance stage possible usefulness target complementing                                              prominent erythrocyte stages. <br />  <br />                                              Km P. vivax GK GMP 3.5 &#206;&#188;M, lower value 22 &#206;&#188;M reported                                              P. falciparum GK [28]. GK screen resulted 17 hits (0.3% hit rate) shown                                              Table 2. positive control iodoacetamide IC50 value 36.5 &#206;&#188;M assay <br />                                              conditions used. range guanylate kinase IC50 values 17 hits 0.5 &#206;&#188;M&#226;&#8364;&#8220; 7.8 <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                               Page 7 <br />  <br />  <br />                                              &#206;&#188;M. Seven compounds available powders; reconfirmed 3 showing <br />                                              specificity PvGK (Supplementary Table S1) shown Figure 1D. GK-1                                              nitro groups does represent chemically attractive scaffold unless analogs <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              nitro groups remain active.  compound relatively specific <br />                                              does appear promiscuous inhibitor historical HTS run GNF. <br />                                              Interestingly, screens overlapping activity pathogen-based screens <br />                                              related presence nitro groups. GK-2 GK-3 (Figure 1D)                                              potentially useful tool compounds interrogate malaria parasite biology confirm <br />                                              PvGK target compounds.  GK-2 ammonium salt                                              low likelihood oral bioavailability, GK-3 imine napthoquinone                                              stability issues trap electrophiles;  ideal starting point medical <br />                                              chemistry efforts. <br />  <br />                                              OMPDC pyrimidine biosynthesis enzyme downstream validated target <br />                                              dihydroorotate dehydrogenase [46]. approximate Km orotidine 5&#226;&#8364;&#178;-monophosphate <br />                                              (OMP) ~0.2 &#206;&#188;M, lower previously reported value 13.4 &#206;&#188;M (PMID <br />                                              15683248). OMPDC screen resulted 26 hits approximate hit rate 0.5% <br />                                              (Table 2). IC50 values ranged 0.22 &#206;&#188;M 10 &#206;&#188;M P. falciparum EC50 values <br />                                              ranged 0.176 &#206;&#188;M 1.7 &#206;&#188;M. 11 powders available reconfirmation                                              reconfirmed, identified fluorescence quenchers                                              false positives. Unfortunately, attractive hit chemical standpoint, OMPDC-1 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              (Fig. 1E), weak inhibitor OMPDC (IC50 19.7 &#206;&#188;M), potent                                              cellular P. falciparum assay. OMPDC-1 useful tool compound investigation <br />                                              effects parasite OMPDC inhibition. <br />  <br />                                              dUTPase protects DNA integrity preventing buildup dUTP conversion                                              <span id='am-219' about='obo:IMR_0200008' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-220' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-221' property="oboInOwl:hasDbXref" content="KEGG:C00365" datatype="xsd:string"></span><span id='am-222' property="oboInOwl:id" content="IMR:0200008" datatype="xsd:string"></span><span id='am-223' property="rdfs:label" content="dUMP" datatype="xsd:string"></span>dUMP</span>, converted <span id='am-61' about='obo:IMR_0200084' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-62' property="rdfs:label" content="dTTP" datatype="xsd:string"></span><span id='am-63' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-64' property="oboInOwl:hasDbXref" content="KEGG:C00459" datatype="xsd:string"></span><span id='am-65' property="oboInOwl:id" content="IMR:0200084" datatype="xsd:string"></span>dTTP</span> used DNA synthesis [47]. Km                                              dUTPase dUTP measured 4.5 &#206;&#188;M, somewhat higher literature value                                              1.9 &#206;&#188;M [48]. positive control used dUTPase inhibition 2&#226;&#8364;&#178;-deoxy-5&#226;&#8364;&#178;-O- <br />                                              (triphenylmethyl)<span id='am-208' about='obo:IMR_0200021' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-209' property="oboInOwl:id" content="IMR:0200021" datatype="xsd:string"></span><span id='am-210' property="rdfs:label" content="Uridine" datatype="xsd:string"></span><span id='am-211' property="oboInOwl:hasDbXref" content="KEGG:C00299" datatype="xsd:string"></span><span id='am-212' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>uridine</span>, IC50 value 2.4 &#206;&#188;M assay conditions. <br />                                              dUTPase screen resulted 95 hits (3.1% hit rate) positive control inhibitor <br />                                              performed expected. 91 compounds available powders retested dose- <br />                                              response reconfirmation screen IC50 values. parallel, hits counterscreened                                              potential inhibit components PPi detection kit Lonza.                                              counterscreen tested putative hits ability inhibit direct detection ~5 &#206;&#188;M PPi, <br />                                              using detection reagents primary dUTPase. positive control showed                                              expected inhibition profile dUTPase assay inhibition counterscreen. <br />                                               hits inhibitors counterscreen. conclusion, did                                              identify hits inhibitors dUTPase. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               3.5. Enzymes involved pathways adding <span id='am-45' about='obo:IMR_0001362' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-46' property="obo:IAO_0000115" content="Organic molecule that is insoluble in water but tends to dissolve in nonpolar organic solvent." datatype="xsd:string"></span><span id='am-47' property="oboInOwl:id" content="IMR:0001362" datatype="xsd:string"></span><span id='am-48' property="rdfs:label" content="lipid" datatype="xsd:string"></span><span id='am-49' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-50' property="oboInOwl:hasDbXref" content="CHEBI:25054" datatype="xsd:string"></span>lipid</span> groups proteins (NMT FPPS) <br />                                              NMT transfers myristate (saturated C14 fatty acid) groups N-terminal <span id='am-184' about='obo:IMR_0100118' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001695 obo:IMR_0000001 obo:IMR_0100116'><span id='am-185' property="oboInOwl:hasExactSynonym" content="Gly" datatype="xsd:string"></span><span id='am-186' property="rdfs:label" content="glycine" datatype="xsd:string"></span><span id='am-187' property="rdfs:label" content="Glycine" datatype="xsd:string"></span><span id='am-188' property="oboInOwl:hasDbXref" content="KEGG:C00037" datatype="xsd:string"></span><span id='am-189' property="oboInOwl:hasExactSynonym" content="Aminoacetic acid" datatype="xsd:string"></span><span id='am-190' property="rdfs:label" content="Aminoacetic acid" datatype="xsd:string"></span><span id='am-191' property="rdfs:label" content="Gly" datatype="xsd:string"></span><span id='am-192' property="oboInOwl:id" content="IMR:0100118" datatype="xsd:string"></span><span id='am-193' property="oboInOwl:hasAlternativeId" content="IMR:0200057" datatype="xsd:string"></span><span id='am-194' property="oboInOwl:hasExactSynonym" content="Glycine" datatype="xsd:string"></span><span id='am-195' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>glycine</span> residues                                              substrate proteins, increasing hydrophobicity promoting associations                                              membranes proteins [49]. NMT Km 7 &#206;&#188;M myristoyl-CoA 21 &#206;&#188;M <br />                                              synthetic peptide GSSYSRKNK. <br />  <br />                                              positive control inhibitor NMT inhibition, aurintricarboxylate, IC50 ~3 <br />                                              &#206;&#188;M. NMT screen resulted 7 hits overall hit rate 0.2%. positive control <br />                                              inhibitor, aurintricarboxylate, performed expected. 5 compounds available                                              reconfirmed inihibition. NMT-1 (Fig. 1F) did score past screens performed                                              GNF, suggesting specific activity NMT. single nitro group,                                              concomitant risk mutagenic potential [50], compound useful tool <br />                                              compound validate NMT viable drug target. structures  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                            Page 8 <br />  <br />  <br />                                              chemically attractive drug discovery, contain structural alerts,                                              nitro groups NMT-1 NMT-3 ammonium salts NMT-2, 4, 5                                               Supplementary Table S1), possibly used tool compounds NMT <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              inhibition. <br />  <br />                                              FPPS involved post-translational modification proteins protein <br />                                              farnesylation. FPPS produces <span id='am-15' about='obo:IMR_0200097' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-16' property="oboInOwl:hasDbXref" content="KEGG:C00448" datatype="xsd:string"></span><span id='am-17' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-18' property="rdfs:label" content="Farnesyl diphosphate" datatype="xsd:string"></span><span id='am-19' property="oboInOwl:id" content="IMR:0200097" datatype="xsd:string"></span>farnesyl diphosphate</span>  k  farnesyl pyrophosphate FPP), <br />                                              used protein farnesyltransferase (PFT), validated target Plasmodium <br />                                              [51], attachment farnesyl groups proteins. Km&#226;&#8364;&#8482;s FPPS 8 &#206;&#188;M geranyl <br />                                              diphosphate 9 &#206;&#188;M isopentenyl diphosphate. positive control inhibitor (1- <br />                                              hydroxy-2-phenylethylidene)bis-phosphonic acid IC50 7.7 &#206;&#188;M FPPS                                              EC50 value ~7.05 &#206;&#188;M P. falciparum vitro. FPPS screen resulted 147 <br />                                              hits. Unfortunately, exception positive control, (1-hydroxy-2- <br />                                              phenylethylidene)bis-phosphonic acid, hits reconfirmed FPPS assay                                              hits counterscreen (conducted described dUTPase). conclusion,                                              compounds hit specificity FPPS exception positive control <br />                                              inhibitor. <br />  <br />                               3.6. Glutamate dehydrogenase <br />                                              GDH provides NADPH biosynthesis <span id='am-66' about='obo:IMR_0100173' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001700'><span id='am-67' property="obo:IAO_0000115" content="A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides." datatype="xsd:string"></span><span id='am-68' property="rdfs:label" content="L-Glutathione" datatype="xsd:string"></span><span id='am-69' property="oboInOwl:hasExactSynonym" content="L-Glutathione" datatype="xsd:string"></span><span id='am-70' property="rdfs:label" content="5-L-Glutamyl-L-cysteinylglycine" datatype="xsd:string"></span><span id='am-71' property="rdfs:label" content="Reduced glutathione" datatype="xsd:string"></span><span id='am-72' property="oboInOwl:hasExactSynonym" content="Reduced glutathione" datatype="xsd:string"></span><span id='am-73' property="oboInOwl:id" content="IMR:0100173" datatype="xsd:string"></span><span id='am-74' property="oboInOwl:hasDbXref" content="KEGG:C00051" datatype="xsd:string"></span><span id='am-75' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-76' property="oboInOwl:hasExactSynonym" content="5-L-Glutamyl-L-cysteinylglycine" datatype="xsd:string"></span><span id='am-77' property="rdfs:label" content="glutathione" datatype="xsd:string"></span>glutathione</span> reductase, oxidative stress- <br />                                              fighting enzyme thought essential [25]. contrast mammalian GDH enzyme, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              PfGDH highly specific NADP+ NADPH, suggesting exploitable differences <br />                                              mammalian parasite enzymes. Km&#226;&#8364;&#8482;s estimated 16 &#206;&#188;M                                              NADP+ 0.8 mM glutamate, consistent literature values 20 &#206;&#188;M 1 mM, <br />                                              respectively [25]. GDH screen resulted 164 hits, 2.9% hit rate;  activity <br />                                              hits GDH weak. 78 powders available tested                                              reconfirmation hits reconfirmed assay conditions used. decrease                                              assay stringency increase sensitivity inhibitors, concentration substrate <br />                                              [NADP+] reduced 400 &#206;&#188;M 50 &#206;&#188;M, hits reconfirmed. conclusion, <br />                                              hits identified GDH. <br />  <br />                               4. Discussion <br />                                              availability large compound collections automated robotic systems ultra high- <br />                                              throughput screening commonplace pharmaceutical companies,                                              frequent academia. collection antimalarial chemical inhibitors <br />                                              identified screening non-proprietary compound collections. application,                                              attempted link antimalarial compounds possible protein targets.                                              cell-active compounds tested high-throughput assays enzymes believed NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              potential drug targets based considerations essentiality, druggability, <br />                                              selectivity, amenability high-throughput screening (section 2.2 Table 1).                                              enzymes included involved nucleotide metabolism (AdSS, dUTPase, GK,                                              OMPDC) attachment lipid groups proteins (NMT FPPS)                                              components key metabolic pathways (CK, GDH, SAHH).                                              unable detect inhibitors dUTPase, FPPS GDH, identified inhibitors AdSS, <br />                                              GK, OMPDC, NMT, CK, SAHH potential starting points medicinal chemistry                                              tool compounds Plasmodium enzymes. view, results validate <br />                                              disprove wisdom target selection strategy. disappointed                                              potent inhibitors enzymes chosen;  screen larger chemical library <br />                                              retrieved compounds suitable development leads good activity <br />                                              enzymes parasite cells. <br />  <br />  <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                              Page 9 <br />  <br />  <br />                                              IC50 values preliminary hits enzymes checked repurchased compounds <br />                                              (Table 3 Supplementary Table S1). Reversible inhibitors generally act                                              intracellular targets IC50 lower EC50 parasite.  NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              compound concentrations target-based hits required inhibit enzyme activity <br />                                              higher concentrations needed inhibit P. falciparum growth.                                              number possible explanations cellular enzymatic discrepancy.                                               targets inhibited antimalarial compounds                                               primary, target compound; inhibition protein  non-protein <br />                                              targets) contribute cellular activity [52]. Second, possible mechanism <br />                                              compound affecting parasitic activity completely unrelated                                              biochemical activity reported   EC50 values lower relative                                              biochemical IC50 values test compound accumulates higher concentrations inside <br />                                              parasite. Lastly, comparing enzyme activity antimalarial activity                                              particularly helpful, given unavoidable differences intracellular vitro <br />                                              conditions (e.g. substrate concentrations), unless comparing structure activity <br />                                              relationships (SAR) set chemically related analogs relative enzyme                                              antimalarial inhibition. Derivation pharmacophore correlation enzyme- <br />                                              based parasite-based inhibition needed identify meaningful SAR correlations                                              link target hits observed cell-based phenotype. highest priority follow <br />                                              enzyme inhibitors IC50&#226;&#8364;&#8482;s &lt; EC50&#226;&#8364;&#8482;s, investigations associations                                              high-value compounds targets prove worthwhile chemically validate targets. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              targets (dUTPase, GDH FPPS) lacked hits compounds tested.                                              possible enzymes essential parasite assay conditions. <br />                                              Alternatively, broader library antimalarial compounds selected <br />                                              lacking chemical composition capable inhibiting enzymes. <br />                                              Regarding possibility, enzymes predicted moderate high <br />                                              druggability according silico methods  Table 1). approach offered test                                              silico predictions suggested benefit refinement. <br />  <br />                                              test inhibition particular biochemical target causal antimalarial <br />                                              activity, approaches possible. include:   allowing cultures evolve <br />                                              resistance compound determining mutations occur gene                                              presumed target [53]; (b) studying compounds chemically related original hit                                              looking correlation IC50&#226;&#8364;&#8482;s presumed target EC50&#226;&#8364;&#8482;s                                              parasite [54]; (c) determining overexpression putative target overcomes                                              inhibition observed presence compound [55]  genetic manipulation                                              Plasmodium challenging); (d) detecting buildup presumed target&#226;&#8364;&#8482;s substrate <br />                                              depletion product extracts compound-treated cells [56&#226;&#8364;&#8220;58], NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              determining parasite growth restored supplementation media                                              missing product [59]; (e) using compounds affinity probes isolate target <br />                                              proteins cell lysates [60]. <br />  <br />                                              Despite extensive screening work reported  mechanisms action 5,655 <br />                                              antimalarial compounds generally remain elusive.  modifications present <br />                                              approach lead greater success identifying mechanisms action. example, <br />                                              studying compounds EC50&#226;&#8364;&#8482;s &gt;1.25 &#206;&#188;M enable discovery weak <br />                                              activity parasite EC50/IC50 data strongly point particular target. <br />                                              Furthermore, considering roughly 2 5% organism&#226;&#8364;&#8482;s genes legitimate <br />                                              potential drug targets [61], number proteins tested relatively small                                              labor-intensive requirement optimizing separate biochemical assay protein. <br />                                              generic method assessing compound-protein binding, thermal melting [32]                                              Surface Plasmon Resonance [62], allow proteins studied simultaneously, <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                                               Page 10 <br />  <br />  <br />                                              increasing odds identified likely targets antiparasitic <br />                                              compounds. Finally, possible similar screening efforts instead focus                                              finding new scaffolds previously validated targets. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              conclusion, data support original proposition target-based drug <br />                                              discovery accelerated starting cell-active compounds. early                                              say enzyme-compound associations identified screens represent <br />                                              compound&#226;&#8364;&#8482;s true mechanism action inhibiting parasite growth, compounds <br />                                              utility exploring biology surrounding possible targets.                                              tool compounds employed basic studies enzyme function pathway biology <br />                                              starting points structure-activity relationship (SAR) selectivity studies. <br />                                              Screens kind performed yield valuable information                                              result identification biochemically potent lead compounds drug development. <br />  <br />                               Supplementary Material <br />                                              Refer Web version PubMed Central supplementary material. <br />  <br />  <br />                               Acknowledgments <br />                                              efforts possible combination pharmaceutical resources (Novartis), funding                                              Medicines Malaria Venture (MMV) partnership academia  University Washington). thank <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              Thierry Diagana Novartis Institute Tropical Diseases (NITD) Singapore help planning project <br />                                              critical review manuscript, Christophe Bodenreider NITD sharing unpublished data. <br />  <br />  <br />                               References <br />                                              1. Valderramos SG, Fidock DA. Transporters involved resistance antimalarial drugs. Trends <br />                                                 Pharmacol Sci. 2006; 27:594&#226;&#8364;&#8220;601. [PubMed: 16996622] <br />                                              2. Ekland EH, Fidock DA. vitro evaluations antimalarial drugs relevance clinical <br />                                                 outcomes. Int J Parasitol. 2008; 38:743&#226;&#8364;&#8220;7. [PubMed: 18406409] <br />                                              3. Nkrumah LJ, Riegelhaupt PM, Moura P, et al. Probing multifactorial basis Plasmodium <br />                                                 falciparum quinine resistance: evidence strain-specific contribution sodium-proton <br />                                                 exchanger PfNHE. Mol Biochem Parasitol. 2009; 165:122&#226;&#8364;&#8220;31. [PubMed: 19428659] <br />                                              4. Sidhu AB, Valderramos SG, Fidock DA. pfmdr1 mutations contribute quinine resistance                                                 enhance mefloquine artemisinin sensitivity Plasmodium falciparum. Mol Microbiol. 2005; <br />                                                 57:913&#226;&#8364;&#8220;26. [PubMed: 16091034] <br />                                              5. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA. Decreasing <br />                                                 pfmdr1 copy number plasmodium falciparum malaria heightens susceptibility mefloquine, <br />                                                 lumefantrine, halofantrine, quinine, artemisinin. J Infect Dis. 2006; 194:528&#226;&#8364;&#8220;35. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                 16845638] <br />                                              6. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance Plasmodium falciparum malaria <br />                                                 parasites conferred pfcrt mutations. Science. 2002; 298:210&#226;&#8364;&#8220;3. [PubMed: 12364805] <br />                                              7. Eastman RT, Fidock DA. Artemisinin-based combination therapies: vital tool efforts                                                 eliminate malaria. Nat Rev Microbiol. 2009; 7:864&#226;&#8364;&#8220;74. [PubMed: 19881520] <br />                                              8. Dondorp  Nosten F, Yi P, et al. Artemisinin resistance Plasmodium falciparum malaria. N <br />                                                 Engl J Med. 2009; 361:455&#226;&#8364;&#8220;67. [PubMed: 19641202] <br />                                              9. Lim P, Alker AP, Khim N, et al. Pfmdr1 copy number arteminisin derivatives combination <br />                                                 therapy failure falciparum malaria Cambodia. Malar J. 2009; 8:11. [PubMed: 19138391] <br />                                              10. White NJ. Qinghaosu (artemisinin): price success. Science. 2008; 320:330&#226;&#8364;&#8220;4. [PubMed: <br />                                                   18420924] <br />                                              11. Odom AR, Van Voorhis WC. Functional genetic analysis Plasmodium falciparum <br />                                                   deoxyxylulose 5-phosphate reductoisomerase gene. Mol Biochem Parasitol. 2010; 170:108&#226;&#8364;&#8220;11. <br />                                                   [PubMed: 20018214] <br />  <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                                    Page 11 <br />  <br />  <br />                                              12. Slavic K, Straschil U, Reininger L, et al. Life cycle studies hexose transporter                                                  Plasmodium species genetic validation essentiality. Mol Microbiol. 2010 <br />                                              13. Vaughan  O&#226;&#8364;&#8482;Neill MT, Tarun  et al. Type II fatty acid synthesis essential NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  malaria parasite late liver stage development. Cell Microbiol. 2009; 11:506&#226;&#8364;&#8220;20. [PubMed: <br />                                                  19068099] <br />                                              14. Sasaki N, Hirai M, Maeda K, et al. Plasmodium HU homolog, binds plastid DNA <br />                                                  sequence-independent manner, essential parasite&#226;&#8364;&#8482;s survival. FEBS Lett. 2009; 583:1446&#226;&#8364;&#8220; <br />                                                  50. [PubMed: 19358847] <br />                                              15. Gunther S, Matuschewski K, Muller S. Knockout studies reveal important role Plasmodium <br />                                                  lipoic acid protein ligase A1 asexual blood stage parasite survival. PLoS  2009; 4:e5510. <br />                                                  [PubMed: 19434237] <br />                                              16. Sijwali PS, Koo J, Singh N, Rosenthal PJ. Gene disruptions demonstrate independent roles                                                  falcipain cysteine proteases Plasmodium falciparum. Mol Biochem Parasitol. 2006; <br />                                                  150:96&#226;&#8364;&#8220;106. [PubMed: 16890302] <br />                                              17. El Bissati K, Zufferey R, Witola WH, Carter NS, Ullman B, Ben Mamoun C. plasma <br />                                                  membrane permease PfNT1 essential purine salvage human malaria parasite <br />                                                  Plasmodium falciparum. Proc Natl Acad Sci U S  2006; 103:9286&#226;&#8364;&#8220;91. [PubMed: 16751273] <br />                                              18. Omara-Opyene AL, Moura PA, Sulsona CR, et al. Genetic disruption Plasmodium <br />                                                  falciparum digestive vacuole plasmepsins demonstrates functional redundancy. J Biol Chem. <br />                                                  2004; 279:54088&#226;&#8364;&#8220;96. [PubMed: 15491999] <br />                                              19. Krnajski  Gilberger TW, Walter RD, Cowman AF, Muller S. Thioredoxin reductase essential <br />                                                  survival Plasmodium falciparum erythrocytic stages. J Biol Chem. 2002; 277:25970&#226;&#8364;&#8220;5. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  [PubMed: 12004069] <br />                                              20. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs bad bugs: confronting challenges <br />                                                  antibacterial discovery. Nat Rev Drug Discov. 2007; 6:29&#226;&#8364;&#8220;40. [PubMed: 17159923] <br />                                              21. Plouffe D, Brinker  McNamara C, et al. silico activity profiling reveals mechanism                                                  action antimalarials discovered high-throughput screen. Proc Natl Acad Sci U S  2008; <br />                                                  105:9059&#226;&#8364;&#8220;64. [PubMed: 18579783] <br />                                              22. Aguero F, Al-Lazikani B, Aslett M, et al. Genomic-scale prioritization drug targets: TDR <br />                                                  Targets database. Nat Rev Drug Discov. 2008; 7:900&#226;&#8364;&#8220;7. [PubMed: 18927591] <br />                                              23. Menz RI, Cinquin O, Christopherson RI. identification, cloning functional expression                                                  gene encoding orotidine 5&#226;&#8364;&#178;-monophosphate (OMP) decarboxylase Plasmodium <br />                                                  falciparum. Ann Trop Med Parasitol. 2002; 96:469&#226;&#8364;&#8220;76. [PubMed: 12194707] <br />                                              24. Nakanishi M, Iwata  Yatome C, Kitade Y. Purification properties recombinant <br />                                                  Plasmodium falciparum <span id='am-88' about='obo:IMR_0200151' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-89' property="oboInOwl:hasDbXref" content="KEGG:C00021" datatype="xsd:string"></span><span id='am-90' property="rdfs:label" content="S-Adenosyl-L-homocysteine" datatype="xsd:string"></span><span id='am-91' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-92' property="oboInOwl:id" content="IMR:0200151" datatype="xsd:string"></span>S-adenosyl-L-homocysteine</span> hydrolase. J Biochem. 2001; 129:101&#226;&#8364;&#8220;5. <br />                                                  [PubMed: 11134963] <br />                                              25. Wagner JT, Ludemann H, Farber PM, Lottspeich F, Krauth-Siegel RL. Glutamate dehydrogenase, <br />                                                  marker protein Plasmodium falciparum--cloning, expression characterization                                                  malarial enzyme. Eur J Biochem. 1998; 258:813&#226;&#8364;&#8220;9. [PubMed: 9874251] <br />                                              26. Choubey V, Guha M, Maity P, et al. Molecular characterization localization Plasmodium <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  falciparum choline kinase. Biochim Biophys Acta. 2006; 1760:1027&#226;&#8364;&#8220;38. [PubMed: 16626864] <br />                                              27. Gunaratne RS, Sajid M, Ling  Tripathi R, Pachebat JA, Holder AA. Characterization N- <br />                                                  myristoyltransferase Plasmodium falciparum. Biochem J. 2000; 348(Pt 2):459&#226;&#8364;&#8220;63. [PubMed: <br />                                                  10816442] <br />                                              28. Kandeel M, Nakanishi M, Ando T, et al. Molecular cloning, expression, characterization                                                  mutation Plasmodium falciparum guanylate kinase. Mol Biochem Parasitol. 2008; 159:130&#226;&#8364;&#8220;3. <br />                                                  [PubMed: 18374996] <br />                                              29. Jayalakshmi R, Sumathy K, Balaram H. Purification characterization recombinant <br />                                                  Plasmodium falciparum adenylosuccinate synthetase expressed Escherichia coli. Protein Expr <br />                                                  Purif. 2002; 25:65&#226;&#8364;&#8220;72. [PubMed: 12071700] <br />                                              30. Whittingham JL, Leal  Nguyen C, et al. dUTPase platform antimalarial drug design: <br />                                                  structural basis selectivity class <span id='am-137' about='obo:IMR_0001697' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001698'><span id='am-138' property="oboInOwl:hasDbXref" content="CHEBI:25611" datatype="xsd:string"></span><span id='am-139' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-140' property="rdfs:label" content="nucleoside" datatype="xsd:string"></span><span id='am-141' property="oboInOwl:id" content="IMR:0001697" datatype="xsd:string"></span>nucleoside</span> inhibitors. Structure. 2005; 13:329&#226;&#8364;&#8220;38. <br />                                                  [PubMed: 15698576] <br />  <br />  <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                                 Page 12 <br />  <br />  <br />                                              31. Phillips MA, Coffino P, Wang CC. Cloning sequencing ornithine decarboxylase gene <br />                                                  Trypanosoma brucei. Implications enzyme turnover selective difluoromethylornithine <br />                                                  inhibition. J Biol Chem. 1987; 262:8721&#226;&#8364;&#8220;7. [PubMed: 3036823] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              32. Crowther GJ, Napuli AJ, Thomas AP, et al. Buffer optimization thermal melt assays                                                  Plasmodium proteins detection small-molecule ligands. Journal Biomolecular Screening. <br />                                                  2009; 14:700&#226;&#8364;&#8220;707. [PubMed: 19470714] <br />                                              33. Crowther GJ, P, Rodenbough PP, et al. Use thermal melt curves assess quality                                                  enzyme preparations. Anal Biochem. 2010; 399:268&#226;&#8364;&#8220;75. [PubMed: 20018159] <br />                                              34. Rahlfs S, Koncarevic S, Iozef R, et al. Myristoylated adenylate kinase-2 Plasmodium falciparum <br />                                                  forms heterodimer myristoyltransferase. Mol Biochem Parasitol. 2009; 163:77&#226;&#8364;&#8220;84. <br />                                                  [PubMed: 18973776] <br />                                              35. Wright SK, Viola  Evaluation methods quantitation cysteines proteins. Anal <br />                                                  Biochem. 1998; 265:8&#226;&#8364;&#8220;14. [PubMed: 9866701] <br />                                              36. Liou JY, Dutschman GE, Lam W, Jiang  Cheng YC. Characterization human UMP/CMP <br />                                                  kinase phosphorylation D- L-form deoxycytidine analogue monophosphates. Cancer <br />                                                  Res. 2002; 62:1624&#226;&#8364;&#8220;31. [PubMed: 11912132] <br />                                              37. Choubey V, Maity P, Guha M, et al. Inhibition Plasmodium falciparum choline kinase                                                  hexadecyltrimethylammonium bromide: possible antimalarial mechanism. Antimicrob Agents <br />                                                  Chemother. 2007; 51:696&#226;&#8364;&#8220;706. [PubMed: 17145794] <br />                                              38. Ancelin ML, Vial HJ. Quaternary ammonium compounds efficiently inhibit Plasmodium <br />                                                  falciparum growth vitro impairment choline transport. Antimicrob Agents Chemother. <br />                                                  1986; 29:814&#226;&#8364;&#8220;20. [PubMed: 3524430] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              39. Tanaka N, Nakanishi M, Kusakabe Y, et al. Crystal structure S-adenosyl-<span id='am-132' about='obo:IMR_0200039' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-133' property="oboInOwl:hasDbXref" content="KEGG:C00155" datatype="xsd:string"></span><span id='am-134' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-135' property="rdfs:label" content="L-Homocysteine" datatype="xsd:string"></span><span id='am-136' property="oboInOwl:id" content="IMR:0200039" datatype="xsd:string"></span>L-homocysteine</span> <br />                                                  hydrolase human malaria parasite Plasmodium falciparum. J Mol Biol. 2004; 343:1007&#226;&#8364;&#8220; <br />                                                  17. [PubMed: 15476817] <br />                                              40. Greenslade FC, Scott CK, Newquist KL, Krider KM, Chasin M. Heterogeneity biochemical <br />                                                  actions vasodilators. J Pharm Sci. 1982; 71:94&#226;&#8364;&#8220;100. [PubMed: 6276530] <br />                                              41. Mett H, Gyr K, Zak O, Vosbeck K. Duodeno-pancreatic secretions enhance bactericidal activity                                                  antimicrobial drugs. Antimicrob Agents Chemother. 1984; 26:35&#226;&#8364;&#8220;8. [PubMed: 6236746] <br />                                              42. Raman J, Mehrotra S, Anand RP, Balaram H. Unique kinetic mechanism Plasmodium <br />                                                  falciparum adenylosuccinate synthetase. Mol Biochem Parasitol. 2004; 138:1&#226;&#8364;&#8220;8. [PubMed: <br />                                                  15500910] <br />                                              43. Kandeel M, Kitade Y. Molecular characterization, heterologous expression kinetic analysis                                                  recombinant Plasmodium falciparum thymidylate kinase. J Biochem. 2008; 144:245&#226;&#8364;&#8220;50. <br />                                                  [PubMed: 18477629] <br />                                              44. Kandeel M, Kitamura Y, Kitade Y. exceptional properties Plasmodium deoxyguanylate <br />                                                  pathways potential area metabolic drug discovery studies. Nucleic Acids Symp Ser <br />                                                  (Oxf). 2009:39&#226;&#8364;&#8220;40. <br />                                              45. Tarun  Peng X, Dumpit RF, et al. combined transcriptome proteome survey malaria <br />                                                  parasite liver stages. Proc Natl Acad Sci U S  2008; 105:305&#226;&#8364;&#8220;10. [PubMed: 18172196] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              46. Gujjar R, Marwaha  El Mazouni F, et al. Identification metabolically stable <br />                                                  triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor antimalarial activity                                                  mice. J Med Chem. 2009; 52:1864&#226;&#8364;&#8220;72. [PubMed: 19296651] <br />                                              47. Nguyen C, Kasinathan G, Leal-Cortijo  et al. Deoxyuridine triphosphate nucleotidohydrolase                                                  potential antiparasitic drug target. J Med Chem. 2005; 48:5942&#226;&#8364;&#8220;54. [PubMed: 16161998] <br />                                              48. Quesada-Soriano  Leal  Casas-Solvas JM, et al. Kinetic thermodynamic characterization                                                  dUTP hydrolysis Plasmodium falciparum dUTPase. Biochim Biophys Acta. 2008; 1784:1347&#226;&#8364;&#8220; <br />                                                  55. [PubMed: 18586121] <br />                                              49. Gelb MH, Van Voorhis WC, Buckner FS, et al. Protein farnesyl N-myristoyl transferases: <br />                                                  piggyback medicinal chemistry targets development antitrypanosomatid antimalarial <br />                                                  therapeutics. Mol Biochem Parasitol. 2003; 126:155&#226;&#8364;&#8220;63. [PubMed: 12615314] <br />                                              50. Orsiere T, Meo M, Rathelot P, et al. Implication nitro group reduction mutagenic                                                  chromosome damaging activities 22 new 5-nitroisoquinolines Salmonella mutagenicity <br />  <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                                  Page 13 <br />  <br />  <br />                                                  test cytokinesis-blocked micronucleus assay. Food Chem Toxicol. 2003; 41:275&#226;&#8364;&#8220;90. <br />                                                  [PubMed: 12480303] <br />                                              51. Fletcher S, Cummings CG, Rivas K, et al. Potent, Plasmodium-selective farnesyltransferase <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  inhibitors arrest growth malaria parasites: structure-activity relationships                                                  ethylenediamine-analogue scaffolds homology model validation. J Med Chem. 2008; <br />                                                  51:5176&#226;&#8364;&#8220;97. [PubMed: 18686940] <br />                                              52. Hopkins AL. Network pharmacology: paradigm drug discovery. Nat Chem Biol. 2008; <br />                                                  4:682&#226;&#8364;&#8220;90. [PubMed: 18936753] <br />                                              53. Dharia NV, Sidhu AB, Cassera MB, et al. Use high-density tiling microarrays identify <br />                                                  mutations globally elucidate mechanisms drug resistance Plasmodium falciparum. <br />                                                  Genome Biol. 2009; 10:R21. [PubMed: 19216790] <br />                                              54. Mukkamala D, JH, Cass LM, Chang TK, Oldfield E. Bisphosphonate inhibition                                                  Plasmodium farnesyl diphosphate synthase general method predicting cell-based activity <br />                                                  enzyme data. J Med Chem. 2008; 51:7827&#226;&#8364;&#8220;33. [PubMed: 19053772] <br />                                              55. Luesch H, Wu TY, Ren P, Gray NS, Schultz PG, Supek F. genome-wide overexpression screen <br />                                                  yeast small-molecule target identification. Chem Biol. 2005; 12:55&#226;&#8364;&#8220;63. [PubMed: <br />                                                  15664515] <br />                                              56. Hankins  Gillespie JR, Aikenhead K, Buckner FS. Upregulation sterol C14-demethylase <br />                                                  expression Trypanosoma cruzi treated sterol biosynthesis inhibitors. Mol Biochem <br />                                                  Parasitol. 2005; 144:68&#226;&#8364;&#8220;75. [PubMed: 16165233] <br />                                              57. Seymour KK, Lyons SD, Phillips L, Rieckmann KH, Christopherson RI. Cytotoxic effects                                                  inhibitors novo pyrimidine biosynthesis Plasmodium falciparum. Biochemistry. 1994; <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                  33:5268&#226;&#8364;&#8220;74. [PubMed: 7909690] <br />                                              58. Vial HJ, Thuet MJ, Ancelin ML, Philippot JR, Chavis C. <span id='am-28' about='obo:IMR_0001356' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001362'><span id='am-29' property="oboInOwl:id" content="IMR:0001356" datatype="xsd:string"></span><span id='am-30' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-31' property="oboInOwl:hasDbXref" content="CHEBI:26063" datatype="xsd:string"></span><span id='am-32' property="rdfs:label" content="phospholipid" datatype="xsd:string"></span>Phospholipid</span> metabolism new target <br />                                                  malaria chemotherapy. Mechanism action D-2-amino-1-butanol. Biochem Pharmacol. <br />                                                  1984; 33:2761&#226;&#8364;&#8220;70. [PubMed: 6431995] <br />                                              59. Roberts F, Roberts CW, Johnson JJ, et al. Evidence shikimate pathway apicomplexan <br />                                                  parasites. Nature. 1998; 393:801&#226;&#8364;&#8220;5. [PubMed: 9655396] <br />                                              60. Kato N, Sakata T, Breton G, et al. Gene expression signatures small-molecule compounds link <br />                                                  protein kinase Plasmodium falciparum motility. Nat Chem Biol. 2008; 4:347&#226;&#8364;&#8220;56. [PubMed: <br />                                                  18454143] <br />                                              61. Hopkins AL, Groom CR. druggable genome. Nat Rev Drug Discov. 2002; 1:727&#226;&#8364;&#8220;30. <br />                                                  [PubMed: 12209152] <br />                                              62. Piliarik M, Vaisocherova H, Homola J. Surface plasmon resonance biosensing. Methods Mol Biol. <br />                                                  2009; 503:65&#226;&#8364;&#8220;88. [PubMed: 19151937] <br />                                              63. Hyde JE. Targeting purine pyrimidine metabolism human apicomplexan parasites. Curr <br />                                                  Drug Targets. 2007; 8:31&#226;&#8364;&#8220;47. [PubMed: 17266529] <br />                                              64. Vial HJ, Wein S, Farenc C, et al. Prodrugs bisthiazolium salts orally potent antimalarials. <br />                                                  Proc Natl Acad Sci U S  2004; 101:15458&#226;&#8364;&#8220;63. [PubMed: 15492221] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              65. Jarzyna R, Lenarcik E, Bryla J. Chloroquine potent inhibitor glutamate dehydrogenase                                                  liver kidney-cortex rabbit. Pharmacol Res. 1997; 35:79&#226;&#8364;&#8220;84. [PubMed: 9149320] <br />                                              66. Werner C, Stubbs MT, Krauth-Siegel RL, Klebe G. crystal structure Plasmodium <br />                                                  falciparum glutamate dehydrogenase, putative target novel antimalarial drugs. J Mol Biol. <br />                                                  2005; 349:597&#226;&#8364;&#8220;607. [PubMed: 15878595] <br />                                              67. Martin MB, Grimley JS, Lewis JC, et al. Bisphosphonates inhibit growth Trypanosoma <br />                                                  brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, Plasmodium <br />                                                  falciparum: potential route chemotherapy. J Med Chem. 2001; 44:909&#226;&#8364;&#8220;16. [PubMed: <br />                                                  11300872] <br />  <br />  <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                        Page 14 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              Figure 1. <br />                                              Chemically tractable inhibitors discovered biochemical screens. Abbreviations refer <br />                                              enzymes inhibited:   choline kinase (CK), (B) S-adenosylhomocysteine hydrolase <br />                                              (SAHH), (C) adenylosuccinate synthetase (AdSS), (D) guanylate kinase (GK), (E) OMP <br />                                              decarboxylase (OMPDC), (F) N-myristoyltransferase (NMT). <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                                                Page 15 <br />  <br />  <br />  <br />  <br />                                                                                            Table 1 <br />                            Selection promising drug targets biochemical screens <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Enzyme (PlasmoDB <span id='am-218' about='oboInOwl:id' typeof='owl:Thing'>ID</span>)                       Essentiality                  Druggability score*   Genome-wide percentile ranking** <br />  <br />                             Adenylosuccinate synthase (PF13_0287)           purine salvage                0.8                        99.5% <br />                                                                             pathway,                                                                             essential                                                                             Plasmodium                                                                             synthesize purines                                                                             novo [63]. <br />  <br />                             Choline kinase (PF14_0020)                      Chemical validation                0.6                        97.9% <br />                                                                             Kennedy pathway                                                                             phosphatidylcholine <br />                                                                             synthesis suggested                                                                             work Henri Vial <br />                                                                             [64]. <br />  <br />                             dUTPase (PF11_0282)                             dUTPase likely                0.6                        99.8% <br />                                                                             essential                                                                             prevents buildup                                                                             dUTP makes dUMP <br />                                                                             dTTP synthesis [47]. <br />                             Farnesyl pyrophosphate synthase                 protein                         0.8                        99.3% <br />                             (PVX_092040)                                    farnesyltransferase                                                                             valid drug target                                                                             Plasmodium [51], FPPS <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                                                                                                                         supplies                                                                             substrate PFT.                                                                             recent paper reported                                                                             ability predict cell- <br />                                                                             killing activity                                                                             bisphosphonates&#226;&#8364;&#8482; <br />                                                                             inhibition FPPS [54]. <br />                             Glutamate dehydrogenase (PF14_0164)             Thought major                 0.8                        99.7% <br />                                                                             source NADPH                                                                             <span id='am-229' about='obo:IMR_0200318' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-230' property="oboInOwl:hasDbXref" content="KEGG:C00051" datatype="xsd:string"></span><span id='am-231' property="oboInOwl:id" content="IMR:0200318" datatype="xsd:string"></span><span id='am-232' property="rdfs:label" content="Glutathione" datatype="xsd:string"></span><span id='am-233' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>glutathione</span> reductase, <br />                                                                             thought                                                                             essential [65].                                                                             based fact <br />                                                                             Plasmodium                                                                             &#226;&#8364;&#339;exposed multiple <br />                                                                             oxidative stress                                                                             high metabolic rate,                                                                             degradation heme                                                                             reactive oxygen species <br />                                                                             imposed host <br />                                                                             immune ? [66]. <br />  <br />                             Guanylate kinase (PVX_099895)                   Based metabolic                    0.2                        98.4% <br />                                                                             maps, guanylate kinase <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                                             appeared                                                                             route                                                                             Plasmodium convert <br />                                                                             GMP GDP dGMP <br />                                                                             dGDP.  possible <br />                                                                             bypass noted                                                                             text.)  expression <br />                                                                             liver stage [45] <br />                                                                             suggests importance                                                                             stage. <br />  <br />                             N-myristoyltransferase (PF14_0127)              argued Gelb et al.              0.8                        98.4% <br />                                                                             [49], &#226;&#8364;&#339;Genetic studies <br />                                                                             shown                                                                             NMT gene essential <br />                                                                             viability range                                                                             species, including <br />                                                                             Drosophila <br />                                                                             melanogaster, S. <br />  <br />  <br />  <br />  <br />                                                   Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                                                                  Page 16 <br />  <br />  <br />  <br />  <br />                                Enzyme (PlasmoDB ID)                           Essentiality                   Druggability score*       Genome-wide percentile ranking** <br />                                                                                    cerevisiae Candida <br />                                                                                    albicans NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                                                    Cryptococcus <br />                                                                                    neoformans.&#226;&#8364;? <br />  <br />                                OMP decarboxylase (PF10_0225)                       novo                     N                              98.6% <br />                                                                                    pyrimidine synthesis <br />                                                                                    pathway,                                                                                    essential                                                                                    Plasmodium                                                                                    does                                                                                    pyrimidine salvage <br />                                                                                    pathway [63].  <br />                                                                                    chemical validation                                                                                    novo pyrimidine <br />                                                                                    pathway comes                                                                                    studies dihydroorotate <br />                                                                                    dehydrogenase [46]. <br />  <br />                                S-adenosylhomocysteine hydrolase (PFE1050w)         methylation                   0.8                              99.9% <br />                                                                                    cycle blockage <br />                                                                                    fatal [39]. <br />  <br />                            * <br />                             Druggability scores taken TDRtargets.org. Scores range 0.0 1.0, 1.0 signifying maximum druggability ~0.2 signifying <br />                            average score. <br />                            ** <br />                               TDRtargets.org used perform multiparameter weighted search, points awarded various features considered desirable NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            potential drug target. Percentiles computed rank-order list genes Plasmodium genome. Points awarded                            follows: 8 points gene life cycle stage (merozoite, early late ring, early late schizont, early late trophozoite)                            expression ranks quintile (80th 100th percentile) given erythrocyte life cycle stage; 4 points gene life <br />                            cycle stage expression 60th 80th percentile; 50 points gene genetic validation (according manual curation                            literature); 35 points gene associated publications (according automated analysis PubMed); 50 points                            gene associated crystal structures; 30 points gene 3D structural model (ModBase); 25 points                            gene lacking ortholog humans; 20 points gene lacking predicted transmembrane domain; 20 points gene coding protein <br />                            100 kilodaltons; 100 points gene coding enzyme; 40 points gene orthologs essential model <br />                            organism; 30 points gene activity assay available. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                      Mol Biochem Parasitol. Author manuscript; available PMC 2012 January 1. <br />                             Crowther et al.                                                                                                                            Page 17 <br />  <br />  <br />  <br />  <br />                                                                                                Table 2 <br />                            Screening reactions detection strategies <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                Enzyme (EC number)                 Chemical reactions                Detection strategy                    Control wells* <br />  <br />                                Adenylosuccinate synthetase (6.3.4.4)   Primary: GTP + IMP + L-           Detect GDP using Cisbio               Hadacidin [42] <br />                                                                        aspartate &#226;&#8224;&#8217; GDP + Pi +            Transcreener ADP kit. <br />                                                                        adenylosuccinate <br />                                Choline kinase (2.7.1.32)               Primary: ATP + choline &#226;&#8224;&#8217;          Detect ADP using Cisbio               choline <br />                                                                        ADP + phosphocholine              Transcreener ADP kit. <br />  <br />                                dUTPase (3.6.1.23)                      Primary: dUTP + <span id='am-104' about='obo:IMR_0200357' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-105' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-106' property="oboInOwl:id" content="IMR:0200357" datatype="xsd:string"></span><span id='am-107' property="oboInOwl:hasDbXref" content="KEGG:C00001" datatype="xsd:string"></span><span id='am-108' property="rdfs:label" content="H2O" datatype="xsd:string"></span>H2O</span> &#226;&#8224;&#8217;             Detect PPi Lonza PPiLight        CAS: 14270-73-6,84472-83-3 <br />                                                                        dUMP + PPi                        kit. <br />  <br />                                Farnesyl pyrophosphate synthase         Primary: geranyl diphosphate      Detect PPi Lonza PPiLight        compound 11 [67] <br />                                (2.5.1.&#226;&#710;&#8217;)                               + isopentenyl diphosphate &#226;&#8224;&#8217;       kit. <br />                                                                        farnesyl diphosphate + PPi <br />  <br />                                Glutamate dehydrogenase (1.4.1.4)       Primary: <span id='am-172' about='obo:IMR_0100119' typeof='owl:Thing obo:IMR_0000967 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0001695 obo:IMR_0000001 obo:IMR_0100116'><span id='am-173' property="rdfs:label" content="glutamic acid" datatype="xsd:string"></span><span id='am-174' property="rdfs:label" content="L-Glutaminic acid" datatype="xsd:string"></span><span id='am-175' property="oboInOwl:hasAlternativeId" content="IMR:0200156" datatype="xsd:string"></span><span id='am-176' property="oboInOwl:hasExactSynonym" content="L-Glutamate" datatype="xsd:string"></span><span id='am-177' property="oboInOwl:hasExactSynonym" content="L-Glutamic acid" datatype="xsd:string"></span><span id='am-178' property="rdfs:label" content="L-Glutamate" datatype="xsd:string"></span><span id='am-179' property="oboInOwl:hasDbXref" content="KEGG:C00025" datatype="xsd:string"></span><span id='am-180' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-181' property="oboInOwl:id" content="IMR:0100119" datatype="xsd:string"></span><span id='am-182' property="rdfs:label" content="L-Glutamic acid" datatype="xsd:string"></span><span id='am-183' property="oboInOwl:hasExactSynonym" content="L-Glutaminic acid" datatype="xsd:string"></span>L-glutamate</span> + H2O        Detect NADPH fluorescence.            glutamate <br />                                                                        + NADP+ &#226;&#8224;&#8217; 2-oxoglutarate <br />                                                                        + <span id='am-78' about='obo:IMR_0200075' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-79' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-80' property="oboInOwl:id" content="IMR:0200075" datatype="xsd:string"></span><span id='am-81' property="rdfs:label" content="NH3" datatype="xsd:string"></span><span id='am-82' property="oboInOwl:hasDbXref" content="KEGG:C00014" datatype="xsd:string"></span>NH3</span> + NADPH + H+ <br />  <br />                                Guanylate kinase (2.7.4.8)              Primary: ATP + GMP &#226;&#8224;&#8217;              Detect ADP GDP using              Iodoacetamide <br />                                                                        ADP + GDP                         Cisbio Transcreener ADP kit. <br />  <br />                                N-myristoyltransferase (2.3.1.97)       Primary: myristoyl-CoA +          Detect CoA&#226;&#8364;&#8482;s free &#226;&#8364;&#8220;SH groups          aurintricarboxylate <br />                                                                        glycylpeptide &#226;&#8224;&#8217; CoA + N-          ThioGlo. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                                        myristoylglycylpeptide <br />  <br />                                OMP decarboxylase (4.1.1.23)            Primary: OMP &#226;&#8224;&#8217; UMP +              Detect ADP using Cisbio               OMP <br />                                                                        ATP CMP kinase: UMP +             Transcreener ADP kit. <br />                                                                        ATP &#226;&#8224;&#8217; UDP + ADP <br />  <br />                                S- adenosylhomocysteine hydrolase       Primary: S-                       Detect homocysteine&#226;&#8364;&#8482;s free &#226;&#8364;&#8220;SH        S- adenosylhomocysteine <br />                                (3.3.1.1)                               adenosylhomocysteine + H2O        groups ThioGlo. <br />                                                                        &#226;&#8224;&#8217; adenosine + homocysteine <br />                                                                        Adenosine deaminase: <br />                                 <br /> </body></html>